Loading
Last Inch Assessment is an optical imaging tool from LEADOPTIK that lets doctors see, during a lung biopsy, whether the needle is inside a small nodule. It is in development and not yet cleared by the FDA.
Last Inch Assessment (LIA) is the flagship technology of LEADOPTIK for pulmonary imaging and biopsy. NCI SBIR grant 1R44CA314574-01 funds its development for transbronchial biopsy of peripheral lung lesions, where, the award abstract says, radial endobronchial ultrasound reaches a diagnostic yield of 56.3 per cent for nodules under 20 mm because the imaging probe and biopsy tool must be exchanged. A clinical adviser quoted by the company says it is preparing for FDA submission.
Real-time microstructure imaging at the tip of the biopsy tool during bronchoscopy, so that the operator can confirm the needle is in the lesion before sampling, as described by the company and its NCI award.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Last Inch Assessment" OR ABSTRACT:"Last Inch Assessment" OR TITLE:"LIA" OR ABSTRACT:"LIA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Last Inch Assessment (LIA), not a curated reading list.
Shares Optical & fluorescence imaging and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/